Improving Cancer Epigenetic Therapy; A Glimpse of NRF2

Tahereh Kashkoulinejad-Kouhi1,∗

1Department of Pathology and Laboratory Medicine, Western University, 339 Windermere Road, London, Ontario, Canada
∗Correspondence should be addressed to Tahereh Kashkoulinejad-Kouhi, taherekashkooli@gmail.com

Received date: April 09, 2023, Accepted date: May 24, 2023

Copyright: © 2023 Kashkoulinejad-Kouhi T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

One of the mechanisms used by epigenetic therapy is the elevation of host cell-derived double stranded RNA (dsRNA) baseline levels through overexpression of genomic repetitive elements especially Alu retroelements. The dsRNAs trigger immunogenic responses since immune system cannot distinguish between endogenous and exogenous dsRNAs derived from viral infections; hence called “Viral mimicry response”. These dsRNAs are recognized by pattern recognition receptors (PRRs) such as MDA-5 which further induce inflammatory responses through interferon secretion. However, the response is limited through the function of some editing enzymes such as ADAR1 which destabilizes the formation of dsRNAs and renders the therapy less efficient through attenuating interferon secretion by immune cells. Since, some cancer cells can survive even after ADAR1 inhibition, it is speculated that there might be other mechanism which contribute to dsRNA destabilization. Since dsRNA formation derived from retroelement transcripts mimics viral infections, we tried to review the mechanistic approaches applied during host-pathogen interaction to highlight a possible candidate which might be cogitable for further investigations in epigenetic therapy. dsRNAs produced by RNA viruses are sensed by PRRs and activate nuclear factor erythroid 2 p45-related factor 2 (NRF2) which further downregulates STING protein and attenuates IFN release. RNA viruses such as SARS-CoV-2 have the potential to impair NRF2 signaling and eliminate its inhibitory effect from STING, leading to excessive release of IFNs and destroy pulmonary cells through cytokine release storm (CRS). Here, we briefly explain that NRF2, in a very downstream side of anti-viral response, might be a potential candidate target in combination with epigenetic therapy to circumvent the limitations in cancer epigenetic therapy.

Keywords: Epigenetic therapy, Viral mimicry, Interferon, Immunotherapy

Cancer and Immune Response

It is well established that cytotoxic CD8+ T cells play integral roles in eliminating malignant transformed cells. Immunotherapies based on T cells have been gathered increasing attention in cancer treatment. A series of conditions is required for immune response to tumor cells. First, tumor cells secrete tumor-associated antigens into the tumor microenvironment, which are then captured by antigen-presenting cell (APC) [1]. Antigen-loaded APCs process and present antigens through major histocompatibility (MHC) complexes to the cell surface and then transfer them to lymphoid organs. There, the selected peptide-MHC complexes are recognized by naïve T cells through T cell receptor (TCR). This induces the priming and activation of effector T cells. Passing through the circulating system, T cells recognize cancer cells by virtue of matching antigens in cancer cells recognized by TCR and peptide-MHC complexes. This recognition leads to cancer cell death by direct and indirect immune attack. A new round of anti-tumor immune response would be triggered through the release of additional antigens from dead tumor cells [2,3].

Role of Epigenetics in Cancer Therapy

One of the major mechanisms in cancer development and progression, is alteration in epigenome profile and aberrant DNA methylation [4-6]. Epigenetic modulation is a heritable DNA modification that changes the appearance of the chromatin window while maintains the DNA sequence intact, leading to gene expression regulation. Eukaryotic genes switch between “on” and “off” state by a variety of mechanisms
Dysregulated patterns of DNA methylation are often associated to frequent mutations in genes that modulate DNA methylation such as DNMT3a and TET2 in human cancers, which leads to impaired gene expression. For example, local hypermethylation of tumor suppressor gene promoters suppresses their expression, which is directly linked with tumorigenesis [12].

Modification of various positions of histones attracted great attention for transcriptional regulation of genes in tumor cells. For example, silencing of repetitive DNA and transposons is highly related to H4K2me3. Loss of H4K20me3 is an important characterization of cancer. DNA methylation together with post-translational modification determine the transcriptional status which leads to tumor progression. In addition, epigenetics also affects anti-tumor immune responses, such as inducing neoantigen production, disrupting antigen presentation mechanisms, promoting inflammatory factor secretion and inducing immunosuppressive effects, thereby exacerbating tumor development [13].

DNA methyltransferase inhibitors (DNMTi) such as cytidine analogues 5-azacytidine (Azacytidine or AZA) and 5-aza-2'-deoxycytidine (Decitabine or DAC) have been synthesized in 1964 as first epigenetic drugs [14]. During DNA replication and transcription, DAC intercalates into DNA and AZA incorporates into both DNA and RNA. It was demonstrated that prolonged treatment with low-doses of AZA can eventually lead to the treatment of myeloplastic syndrome (MDS) [15,16].

Epigenetic Therapy and Immune Response

Immunotherapy meets epigenetic therapy through “viral mimicry” mechanism. This is an immune response induced by elevated levels of endogeneous nucleic acids often primed by overexpression of cellular retrotransposons such as long interspersed nuclear element (LINEs), Alu elements belonging to short interspersed nuclear element (SINEs) and long terminal repeat (LTR)/ endogenous retrovirus (ERVs) which form double stranded RNA (dsRNA) [17]. The ERVs represent a large fraction of repetitive elements in the human genome that are silenced by DNA methylation. Treatment with DNMTis allows cancer cells to enter a “viral mimicry” state in which they behave like virus-infected cells, leading to the activation of the interferon pathway [18].

Recent studies have reported increased levels of cytosolic double stranded RNA (dsRNA), higher than tolerable thresholds, as a cancer therapeutic strategy to promote antiviral responses [19]. For example, in ovarian cancer cell lines, DNMTis trigger the transcription of dsRNA by suppressing silent expression of hypermethylated ERVs. Upregulation of dsRNA activates cytoplasmic dsRNA sensors and downstream signaling pathways which induce interferon (INF)-β signaling [20]. The production of type I and type III IFNs induced by the viral mimicry pathway would increase antigen presentation and processing of cancer cells in the tumor microenvironment. The same finding is observed in colon cancer cells treated with 5-AZA-cdR.

Epigenetic Therapy and ADAR1 Dependency

Most prevalent RNA modification in mammalian cells is Adenosine to inosine (A-to-I) editing catalyzed by adenosine deaminase acting on the double-stranded RNA (ADAR) protein family. This kind of editing is currently known to be involved in the regulation of the immune system, protein recoding, microRNA biogenesis, RNA splicing, and heterochromatin formation. ADAR1 mediated editing occurs within dsRNAs, especially inverted Alu repeats, and is associated to variety of diseases including cancer, neurodegeneration, and metabolic disorders [21].

Epigenetic therapies such as AZA and DAC can perform their function through activating retroelements within human genomes. Studies have been demonstrated that the major source of epidrug-induced immunogenicity are inverted Alu repeats, mostly located downstream of ‘orphan’ CpG islands [22]. The transcript of retroelements can form dsRNA that activates PRRs such as (Melanoma differentiation-associated proteins (MDA-5) and RNA-dependent protein kinase (PKR) [18,20,23-26]. It was shown that upon epigenetic therapy, stimulated RNA sensors induce MAVs aggregation on the mitochondrial surface to activate TBK1 kinase which then phosphorlylatesIRF-3/7 transcription factor, phosphorylated IRF3/7 dimerize and then translocate to nucleus to activate transcription of IFN genes [18,20]. This viral mimicry mechanism induces innate and adaptive immune responses leading to cancer cell suppression [27,28]. However, the clinical efficacy of cancer therapies against epigenetic repressors has been attenuated through ADAR1-based A-to-I editing system, destabilizing inverted repeat Alu dsRNAs [29].

Indeed, cancer cells hijack ADAR1-mediated dsRNA editing to circumvent innate immune responses such as interferon I and III secretion triggered by endogenous dsRNAs. ADAR1 disrupts the RNA duplex formation through dsRNA modification and diminishes sensing of dsRNA by PRRs [29]. Immunostimulatory dsRNA editing through ADAR1 reduces the double stranded to single stranded RNA ratio. This lower ratio of immunostimulatory dsRNAs sensed by PRRs leads to
chronic versus acute IFN production. Cancer cells can escape chronic IFN response triggered by dsRNA. While chronic IFN production augments cancer aggressiveness, excessive or acute release of IFNs halts tumor progression [30]. Cancer cells can escape chronic IFN responses triggered by decreased ratio of dsRNAs. For example, global DNA hypomethylation of LINEs, SINEs, and LTR/ERVs in a subset of pancreatic ductal adenocarcinoma (PDAC) are associated with upregulated dsRNA expression, chronic IFN production accompanied by tumor metastasis and invasion [31].

However, survival of ADAR1-deficient cancer cells raises the question whether ADAR1 is the sole regulator of immune response after epigenetic therapy. Thus, if dsRNA formation cannot be prevented in the upstream, it is reasonable to ponder about manipulation of downstream responses after dsRNA formation and trigger, which leads to cancer invasiveness.

### Double-edged Role of NRF2 in Cancer

NRF2 is a transcription factor which binds to various molecules such as small musculoaponeurotic fibrosarcoma (SMAF) proteins [32] or transcription factors c-Jun and JUND [33], to target antioxidant response elements (AREs), such as genes involved in cellular redox homeostasis, detoxification, metabolic balance, and macromolecular damage repair [34].

NRF2 has multifaceted roles in cancer cells. Although degradation process is the main process regulating NRF2 protein level, the control of NRF2 gene transcription is through its transcriptional start sites containing Myc and Jun binding sites [35]. Thus, the expression of NRF2 and its downstream genes can be augmented significantly by activating the oncogenic alleles of BRAF, C-MYC, and KRAS, reducing intracellular redox environment [36]. The oncogenic KRAS can activate MAPK-mediated NRF2 antioxidant function in pancreatic cancer [37]. Synthetic and extracted NRF2 activators such as curcumin, resveratrol, lycopene, and epigallocatechin-3-gallate can promote antioxidant function of NRF2 and protect the cells from carcinogenic exposure [38-40].

On the other hand, NRF2 inhibitors such as brusatol, retinoic acid, and trigonelline can also be applied as anticancer agents. NRF2 inhibitors diminish drug detoxifying and cleaning enzymes, leading to cancer cell sensitization to chemotherapeutics [40-42].

### NRF2 Anti-inflammatory Role

The activation of NRF2/ARE signaling pathway plays a vital role in the escalation of chronic inflammation which contribute to cancer progression. ROS removal is thought to be the main molecular mechanism behind NRF2-mediated anti-inflammation as a result of upregulation of a large number of cytoprotective enzymes. NRF2 suppresses the activation of the pro-inflammatory genes and promotes the anti-inflammatory signaling [43].

Studies of putative viral cycle of RNA viruses [44] such as SARS-Cov-2 [45], highlights potential crosstalks with NRF2 activation. Upon viral infection, viral dsRNAs can inactivate eukaryotic initiation factor 2 (eIF2) through PKR and PKR-like endoplasmic reticulum kinase (PERK) which can be activated in response to viral infection [46]. PKR can activate autophagy cargo protein p62, which competes with NRF2 for binding KEAP1 [47] and induce autophagic degradation of KEAP1, an E3 ligase substrate adapter protein [48]. This leads to the activation of NRF2 transcriptional activity [45].

Under basal conditions, NRF2 interacts with KEAP1. This leads to the ubiquitination and further proteosomal degradation of NRF2, keeping the NRF2 level in a steady-state condition [34,49,50]. NRF2 is expressed at a steady-state level in the cell despite its high rate of turnover due to a time-elapsed interval (~15 min) between its biosynthesis and degradation. During this interval, NRF2 might transactivate its genes and accomplishes its role in driving their constitutive expression [51]. Viral nucleic acids inactivate KEAP1 through PKR [48]. Indeed, infected cells with viruses recognize viral nucleic acids by cytoplasmic and endosomal receptors, such as RIG1 [52], MDA5, PKR, and cGAS which signals through STING to induce an appropriate immune response. The activation of STING leads to the secretion of IFN I and III through interferon regulatory factor 3 (IRF3) [53]. NRF2 plays its immunoregulatory role by downregulation of STING, alleviating the excessive release of IFNs through STING activity leading to an appropriate immune response. RNA such as SARS-CoV2 (Figure 1) [54,55]. It was reported that lethal viruses have the ability to aberrate NRF2 axis and inhibits its function, leading to release of excessive IFNs, further CRS and irreversible damage to the host tissues [56].

As mentioned earlier, chronic and alleviated release of IFNs can lead to tumor invasion while culling the cancer cell progression requires acute IFN production. The antitumorigenic as well as pro-tumorigenic role of STING has been reported previously in literature [57-60]. Furthermore, the key role of NRF2 in regulating STING has been established. Inhibiting NRF2 can eliminate its controlling effect from STING, allowing acute secretion of IFNs and further tumor rejection.

### dsRNA, ADAR1 and NRF2 Connection

The mechanism by which elevated dsRNAs prime sublethal versus lethal IFN response requires further investigation. Gannon et al. demonstrated that an increased gene expression signature of interferons is predictive of ADAR1-dependency. They implied that despite previous studies, they did not observe any essential correlation between ADAR1 dependency...
and MDAS/MAVs signaling in lung cancer cell lines [61]. They reported that their data are distinct from previously published studies which demonstrated a critical role for MDAS/MAVs pathway in embryonic lethality phenotype found in Adar1⁻/⁻ [62-64].

The question raised is whether the chronic exposure to exogenous viral infection leads to an immune exhaustion and reduces immune response [65]. Another explanation by Gannon et al., was that the downstream pathways that mediate cellular lethality after ADAR deletion may vary depending in the specific cell type, developmental stage and/or malignant nature of the cells under investigation. Additionally, there are several approaches which possibly can disrupt ADAR1 function in cancer cells such as direct enzymatic inhibition of its adenosine deaminase activity. Gannon et al. also reported that p150 isoform of ADAR1 prevents lethality in cancer cell lines at least partly through inhibition of the cytoplasmic RNA sensor PKR [61]. Although studies have shown ADAR1 deficiency decreases RNA editing and augments dsRNA stabilization, high levels of dsRNAs can activate PKR which in turn induce NRF2 activation. The inhibitory effect of NRF2 on STING may attenuate acute release of IFN I and III, which in turn prevent cancer cell death. This might be one reason why some cancer cells survive during epigenetic therapy even with ADAR1 loss of function. Since some studies have not found changes in MDAS/MAVs signaling pathway in cancer cells with ADAR deficiency, the PKR/NRF2/STING axis might be a landscape of more investigation during epigenetic therapy. Furthermore, the constitutive activation of NRF2 signaling pathway in a variety of cancers signifies the importance of this pathway during cancer epigenetic therapy [43].

For a therapy to be effective in cancer treatment it is critical to promote lethal acute immunogenicity rather than chronic immune response which results in cancer aggressiveness. Taking a deep look into mechanisms involved in RNA virus infections which are mostly fatal, can give us some hints to better understand the molecules involved in the crosstalk between epigenetic therapy and immune system and provide us with much comprehensive insight about limitation and the potential therapeutic strategies to overcome epigenetic therapy barricade. Some RNA viruses such as SARS-CoV-2 increase morbidity in patients through activation of CRS, leading to alveolar tissue damage through necrosis and apoptosis. They produce double stranded RNAs that are recognized by PRRs and activate the downstream NRF2 which downregulates STING and alleviates IFN release, leading to an appropriate inflammatory response against virus. However, RNA viruses apply their strategies to hijack STING signaling through suppression of NRF2 [66,67]. Removing NRF2 regulatory effect from STING can increase the magnitude of IFN release. The magnitude of IFN release is the challenging point in the cancer progression and therapy. While an acute IFN secretion leads to cancer cell death, the chronic and moderate IFN release results in cancer progression. In epigenetic therapy, when ADAR1 destabilizes dsRNA formation through its editing system, it can understimulate the PRRs sensing dsRNAs and keep NRF2 at cellular basal levels [51,63,68] and further attenuating pro-inflammatory responses through STING. However, ADAR1 knockdown, increase dsRNA formation which in turn activates NRF2 through PKR function, leading to STING downregulation and the following IFN I and III attenuation (Figure 2). Applying the strategy (ie. NRF2 impairment) that SARS-CoV-2 uses for inflammatory evasion
and cell/tissue damage through acute release of IFNs can be practical for tumor cell damage and loss of cancer cell fitness.

**Conflicts of Interest**

The author has no conflict of interest to disclose.

**References**


22. Deaton AM, Bird A. CpG islands and the regulation of


